Research programme: V 5 - ZymeworksAlternative Names: V-5 - Zymeworks
Latest Information Update: 06 Nov 2014
At a glance
- Originator Zymeworks
- Class Antibodies; Proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Lung cancer; Multiple myeloma; Renal cancer
Most Recent Events
- 06 Nov 2014 Early research in Lung cancer, Multiple myeloma and renal cancer in Canada (unspecified route)